All Systems go for Toray's new cancer agent

Japanese multinational Toray Industries (TYO: 3402) sees its newly-acquired oncology drug as having the potential to treat a wide spectrum of cancer types.

Toray has signed a licensing deal with Systems Oncology, an AI-based biopharmaceutical company, to in-license the rights to TRK-880, a small molecule agent that is activated by an enzyme which is known to be specifically overexpressed in cancer cells across multiple types of cancer.

This enzyme activation produces a large amount of reactive oxygen species in cancer cells, which in turn leads to potent and cancer specific cell death.